Related references
Note: Only part of the references are listed.CANCER Chemotherapy counteracted
Urban Emmenegger et al.
NATURE (2010)
Pharmacogenomics of paclitaxel
Cristina Rodriguez-Antona
PHARMACOGENOMICS (2010)
The FMCA-GM assays, high throughput non-clonogenic alternatives to CFU-GM in preclinical hematotoxicity testing
Caroline Haglund et al.
TOXICOLOGY LETTERS (2010)
Computational studies on self-assembled paclitaxel structures: Templates for hierarchical block copolymer assemblies and sustained drug release
Xin D. Guo et al.
BIOMATERIALS (2009)
Guided molecular missiles for tumor-targeting chemotherapy-case studies using the second-generation taxolds as warheads
Iwaid Ojima
ACCOUNTS OF CHEMICAL RESEARCH (2008)
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Felix Kratz
JOURNAL OF CONTROLLED RELEASE (2008)
Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma
Christopher A. Carter et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Abraxane in the treatment of ovarian cancer: The absence of hypersensitivity reactions
JP Micha et al.
GYNECOLOGIC ONCOLOGY (2006)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
G Bergers et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
S Pennacchietti et al.
CANCER CELL (2003)
Paclitaxel and its formulations
AK Singla et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2002)
Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC)
CJ Langer et al.
EUROPEAN JOURNAL OF CANCER (2000)
Share Paper
